PUNCH03: A phase II study of disitamab vedotin combined with tislelizumab and bacillus Calmette-Guerin (BCG) in Her2-positive high-risk non-muscle-invasive bladder cancer (HR NMIBC).

Authors: Zongren Wang, Bin Huang, Yukun Wu, Jiahao Lei, Lingwu Chen, Junxing Chen

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4624

Source: Full article

TPS4624